Australia consults on third-party conformity assessment
This article was originally published in SRA
Australia’s Therapeutic Goods Administration may begin allowing third-party conformity assessment bodies to examine and certify the quality systems of local medical device manufacturers1. To that end, it has released a consultation document that outlines the principal issues to be considered, the most important of which is determining an appropriate balance in the use of CABs to ensure the timely availability of safe and effective medical devices2. Comments are due by 27 March.
You may also be interested in...
Drug companies in the EU explain how a new pilot scheme on national-level scientific advice service can benefit drug developers.
While the Dutch government negotiates an acceptable price for Leadiant Biosciences’ orphan drug CDCA, a university hospital has resumed supplying pharmacy compounded versions of the drug after addressing initial problems with the sourcing of raw materials.
The European Court of Justice has confirmed the European Medicines Agency’s approach to disclosure of data submitted as part of a marketing authorization application. It is a big disappointment for industry, which nonetheless says it supports responsible data sharing and will support efforts to develop a balanced approach.